Search

Noninvasive imaging plays a pivotal role in assessing epicardial coronary artery anatomy, myocardial perfusion, and ventricular function in patients with known or suspected cardiovascular diseases. The increasing global burden of cardiovascular diseases has led to the introduction of highly sensitive and specific imaging modalities.[1][2] Over the last two decades, the development of new software has contributed tremendously and broadened non-invasive imaging dimensions. Molecular imaging has revolutionized diagnostic imaging by utilizing high spatial and temporal resolution, significantly improving sensitivity and specificity.[3] Because of increasing knowledge of cardiovascular biology and advances in imaging technologies, molecular imaging has become an essential tool in the fields of cardiovascular medicine.[4] Positron emission tomography (PET) is a prime example of molecular imaging, which has contributed immensely to understanding cardiac anatomy and pathophysiology over the last two decades.[5][6] Similar to other molecular imaging, PET utilizes intrinsic tissue characteristics as the source of image contrast, which leads to a better understanding of integrative biology and provides earlier detection and accurate diagnosis of disease.[7] Stress myocardial positron emission tomography with Rubidium (Rb) provides a powerful estimate of cardiovascular mortality and accurately predicts prognosis in patients with coronary artery disease.[8] Whereas PET with 2-deoxy-2-(F) fluoro-D-glucose (F-FDG) has been utilized as the gold standard for assessing myocardial viability with the help of glucose metabolism.[9] The introduction of hybrid positron emission tomography with computed tomography (PET/CT) imaging by utilizing 3-dimensional acquisitions has been demonstrated as an important milestone in the field of myocardial perfusion imaging. It has significantly shortened the imaging protocol and reduced radiation exposure.[10] Cardiac PET has also been proven as an effective non-invasive imaging modality for diagnosing myocardial infiltrative diseases, cardiac ischemia, and cardiac infections.[11][12][13], (Copyright © 2022, StatPearls Publishing LLC.)

Difelikefalin is a medication used to treat and manage uremic pruritis and post-operative pain, which affect the quality of life. It is in the opioid class of medications. This activity describes the mechanism of action, indications, administration, adverse effects, monitoring, and contraindications for difelikefalin therapy pertinent for interprofessional team members in the treatment and management of patients suffering from uremic pruritis or post-operative pain., (Copyright © 2022, StatPearls Publishing LLC.)

The first fruitful pancreatic transplant was carried out by WD Kelly in the year 1966.[1] The results of pancreas transplantation have greatly improved as compared to the first one done in 1966, due to technical improvements and better immunosuppressive therapy over the last three decades.[2] Transplantation of the pancreas is the only near cure treatment for type 1 diabetic patients.[3] After the making of the International Pancreas Transplant Registry in 1984, data on more than 48000 pancreas transplants have been collected in the subsequent 30 years.[4] Diabetes mellitus is the leading cause of end-stage renal disease worldwide.[5]  Kidney transplantation is the treatment of choice for end-stage renal disease, but in diabetic patients, the metabolic disturbances persist and may get worse even when the kidney alone is transplanted.[5] The only treatment that maintains normal glucose levels and normalizes serum levels of glycosylated hemoglobin in type 1 diabetes patients is the pancreas transplantation.[6] 1 yr and 5 yr results of simultaneous kidney and pancreas transplantation are comparable to the kidney, liver, and heart transplantation.[7], (Copyright © 2022, StatPearls Publishing LLC.)